Background Infection about a megaprosthesis is a dreaded complication. Treatment options vary from débridement alone to staged revisions, arthrodesis, and amputation. Indications for how to treat this complication are unclear.
Introduction
The use of megaprostheses for both oncologic and nononcologic indications continues to grow. While infection is a dreaded complication in any arthroplasty, it is an even more difficult situation in patients with megaprostheses, creating difficult treatment decisions. Infection rates in patients with megaprostheses have been quite high yet variable, with studies ranging in rates from 3% to greater than 30% [4, 8-11, 18-20, 26, 33, 36] and even as high as 43% in revised, previously infected patients with megaprostheses [2] . Studies performed in patients with standard arthroplasty have identified many possible, sometimes conflicting, and site-specific risk factors for developing periprosthetic infections, such as increased BMI, male and female sex, American Society of Anesthesiologists status of greater than 3, diabetes, bilateral THAs in the same operative setting, revision surgery, systemic steroid use, and surgical site drainage [27, 31, 34, 35] , which may be reasonably extended to infections about a megaprosthetic implant.
Prophylactic methods, such as the use of a drain tube in standard knee arthroplasties [31] , the use of appropriately timed preoperative or periprocedural (ie, dental) antibiotics [22, 35] , preoperative screening and decolonization of nasal Staphylococcus aureus [32] , or improved soft tissue coverage strategies (eg, gastrocnemius flaps for proximal tibial implants) [3, 14] , reportedly reduce the risk of infection. Implant characteristics may also play a role. Silver-coated megaprostheses, when compared to uncoated titanium implants, reportedly have decreased infection rates [17] and silver appears to not produce toxic effects in rabbits [12] or humans [15] . Gosheger et al. [11] reviewed 197 patients with megaprostheses and those with cobaltchrome implants had more infections than those with titanium implants. Thus, while a concerted effort to prevent periprosthetic infection is underway, this complication remains a major problem. A general consensus on the best way to manage these infections when they do occur is lacking. Multiple treatment strategies have been reported, including one-and two-stage revisions of the implants, irrigation and débridement with retention of hardware, resection arthroplasty with bracing, arthrodesis, and amputation, all with varying levels of success [9, 13, 16, 19, 21, 28, 36, 37] .
Given the relative rarity of indications for megaprostheses, currently reported series [6, 7, 9, 13, 16, 17, 19, 21, 37] of perimegaprosthetic infections are small, ranging from case reports of one to a retrospective review of 66 patients. However, the heterogeneity inherent in these cases makes comparisons difficult and there is always some degree of individualization in choice of treatment. Since these patients typically have complex problems, identification of factors associated with failure is important and perhaps key to determining treatment algorithms. Determining which patients will benefit from the protracted and more aggressive two-stage revision versus those that can be managed more conservatively or should undergo ablation at the outset would benefit surgeon and patient alike.
We therefore determined (1) the incidence of perimegaprosthetic infections, (2) the methods of treatment, (3) the number of patients who failed their original treatment plan, and (4) the characteristics of the infection.
Patients and Methods
From an institutional database, we identified 291 patients who had megaprostheses implanted for both oncologic and nononcologic indications from 2001 to 2011. Within that group, 40 patients were identified and treated for infections about their megaprostheses. A patient with a perimegaprosthetic infection was defined as someone who had a culture-proven infection or culture-negative infection that met clinical criteria for infection of his or her prosthesis (fever, elevated inflammatory markers, pain, abnormal fluid, or periprosthetic abscess) [27, 29, 30] . For this study, we excluded nine patients who (1) had infections treated only medically, (2) had a followup of less than 1 year postoperatively, (3) had infected pelvic and saddle implants, or (4) were lost to followup. These exclusions left 31 patients (Table 1 ). There were 20 women and 11 men. The minimum followup was 1 year (mean, 3.3 years; range, 1-8 years). No patients were recalled specifically for this study; all data were obtained from medical records. From the records, we extracted information related to the host factors, the infection, and the treatment ( Table 2) .
All patients were treated with culture-driven, antibiotic therapy in addition to surgical management. Culturenegative patients were treated with the (presumed) most appropriate antibiotic therapies, as deemed by the infectious disease specialist. Postoperative protocols, including such variables as drainage tubes, weightbearing, and motion allowance, varied according to surgeon preference. Data on erythrocyte sedimentation rate and C-reactive protein were missing for 14 and 13 patients, respectively, and were therefore difficult to evaluate given the large proportion of missing data points. Complete data on BMI and white blood cell count at the time of infection were missing for two patients each and operative times were missing for eight patients (index reconstruction surgery) and four patients (infection surgery) due to incomplete charting or records. Treatment failure was defined as an unplanned reoperation due to infection after his or her initial surgical management of this infection or a death related to the infection.
Results
With 31 of 291 patients with megaprostheses undergoing surgical management for infection, the incidence at our institution was therefore 11%.
Treatment strategies greatly varied, with most patients undergoing either single (n = 7) or multiple (n = 8) irrigation and débridements with retention of hardware or single-stage revisions (n = 11). Four patients underwent a two-stage revision and one underwent a primary amputation for treatment of infection. All patients were simultaneously treated with culture-driven antibiotics or, in the case of negative cultures, those antibiotics deemed appropriate by the infectious disease specialist.
Sixteen of the 31 patients subsequently had treatment failures, with three deaths and 13 patients requiring additional unplanned surgical procedures. The remaining 15 of the 31 patients required no further surgical intervention after they completed their original treatment plan and there were no deaths within this group (Table 2 ). In the irrigation and débridement and single-stage revision combined group, most patients had a treatment failure Eleven of 17 patients 65 years or older experienced treatment failure while five of 14 patients younger than 65 years experienced failure. Of the 11 patients 65 years or older who failed, three died and eight required unplanned reoperations for uncontrolled infections. Five of those reoperations were amputations that ultimately resulted in the eradication of the infections.
Most patients had single-organism infections, and there were five infections with methicillin-resistant S aureus (Table 1) . Three patients had negative cultures despite clinical evidence of infections. Nine patients' infections presented acutely, less than 1 month after megaprosthetic index surgery. Seven patients had a subacute presentation (1-6 months), and 15 presented chronically ([ 6 months after megaprosthetic reconstruction).
Discussion
There is a growing use of megaprostheses in orthopaedics and a high risk of complications with these implants. One of the complications, as demonstrated in many series [6, 7, 9, 11, 13, 14, 16, 17, 19, 21, 25, 37] , is the increased risk of infection. Most reports on this are relatively small in number with substantial heterogeneity. The variation in the patient population cannot be understated. They range from pediatric to elderly, with numerous different combinations of comorbidities and surgical histories. We therefore determined (1) the incidence of perimegaprosthetic infections, (2) the methods of treatment, (3) the number of patient who failed their original treatment plan, and (4) the characteristics of the infection.
This study has a number of limitations. First, despite being one of the larger series on perimegaprosthetic infection in the literature, the numbers remained small, particularly when divided into subgroups. Thus, it is not possible to determine factors associated with failure. Second, the patient population and treatment methods were heterogeneous. This made direct comparisons between treatments impossible and precluded the ability to perform a statistical analysis. Third, the key outcome measure, a treatment failure as defined by an unplanned reoperation or death due to infection, was also heterogeneous, as patients had varied types and degrees of failures. A failure, as defined here, ranged from an additional débridement to the requirement of amputation or death, representing a large morbidity spectrum such that one failure was not equal to another. Fourth, not all data on every patient were collected due to missing items in the electronic and paper records. In particular, a more complete laboratory value profile would have supported diagnoses; however, as pointed out by multiple authors, clinical judgment after evaluating the entire clinical picture is essential when treating periprosthetic joint infections [27, 29, 30] . Finally, a retrospective review introduces several forms of bias into any study with its inherent heterogeneity and lack of control or randomization. Despite all of these limitations, we do believe contributing to and reviewing the available literature on this topic develops an increased understanding of this clinical scenario, which is important for improving study and patient care.
Our incidence of infection of 11% is consistent with 3% to greater than 30% in reported series [4, 8-11, 18-20, 26, 33, 36] . The available studies that specifically describe their respective treatment methods and findings on series of perimegaprosthetic infection were compared (Table 3) . Consistent with these studies, we found higher infection rates in this population than in standard arthroplasties [27, 31, 34, 35] . Many of these patients have a history of radiated tissue, large prostheses with inadequate or marginal soft tissue coverage, and a history of multiple surgeries and revisions, which have frequently been cited as important factors associated with clearing infection [9, 13, 16] . Additional possible risk factors include longer operative times and larger exposures [14] . It appears unresolved as to whether undergoing chemotherapy is a risk factor for both acquiring these periprosthetic joint infections and for being able to clear them [24] . Donati et al. [6, 7] stated obvious signs of infection may be delayed until the end of a chemotherapy course and thus might mask identification of an infection. Hardes et al. [16] noted irradiated tissue is more likely to fail but found no difference with chemotherapy. They and other authors agree the state of the surrounding soft tissue is among the most important factors [9, 13, 16] .
A number of operative management strategies have been described, including irrigation and débridement without revision of the prosthesis, one-stage revision of the prosthesis (primary exchange arthroplasty), two-stage revision of the prosthesis with a cement/antibiotic spacer, resection arthroplasty, arthrodesis, and amputation [2, 8, 9, 13, 19, 28, 33] . All of these methods have proven effective in some situations and failed in others (Table 3 ). Until indications for treatment are delineated, it will remain imperative that discussion with patient and family and proper individualization to the unique clinical picture are performed in accordance with the surgeon's judgment.
Half of our patients had a treatment failure, requiring unplanned reoperations, longer hospital stays, or in three cases, sustained deaths. Those 65 years and older were more likely to fail and accounted for all deaths. The four of five patients with prior joint infection who failed required highlevel amputations and one required repeat débridements with chronic wound vacuum-assisted closure therapies and long-term, oral antibiotic suppression. The one patient who was successfully treated underwent a two-stage revision of components and has been free of recurrent infection for 3 years. When components were not revised, those who had multiple débridements had fewer failures. Most patients who had either two-stage revisions or amputations did not fail. Unfortunately, these numbers were very small, with only five patients satisfying these criteria. The one primary amputation performed and the five salvage amputations were all successful in eradicating infections, preventing further operative interventions and deaths. Studies in the literature do support revisions with preservation of well-fixed stems and two-stage revisions ( Table 3 ). Ultimate function and satisfaction are preserved once infection is cleared and prostheses are reimplanted [9, 13, 16, 19] . Candid discussions with patients regarding the high likelihood of multiple surgeries and the difficulty in eradicating infections in these situations are warranted. For those aged 65 years and older and those with recurrent infections, the high chance of failure must be emphasized.
Finally, in the standard arthroplasty literature, methicillin-resistant Staphylococcus infections have higher failure rates after the gold standard, two-stage revisions than those with sensitive organisms [1, 5, 23] . In the future, larger numbers may bear out which characteristics of infection may have prognostic value in perimegaprosthetic infections. However, it is reasonable to assume more virulent organisms requiring aggressive multistage revisions in standard arthroplasty will require the same in a megaprosthesis for a goal of infection clearance. And, given that most of our infections were at greater than 6 months after megaprosthetic reconstruction, the need for prolonged vigilance against infection in these patients is warranted.
